OMERS ADMINISTRATION Corp Makes New $5.10 Million Investment in Illumina, Inc. $ILMN

Key Points

• OMERS Administration bought 28,992 Illumina shares worth approximately $5.10 million during the second quarter. Institutional investors collectively own 89.42% of the company.
• Illumina exceeded quarterly expectations, reporting $1.31 in EPS versus a $1.23 consensus estimate and $1.16 billion in revenue, up 9.4% year over year. The company issued fiscal 2026 EPS guidance of $5.30–$5.40.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $188.40, while insiders have sold more than 2.09 million shares worth about $401.7 million over the past three months.

OMERS ADMINISTRATION Corp purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 28,992 shares of the life sciences company's stock, valued at approximately $5,098,000.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Elyxium Wealth LLC acquired a new position in Illumina during the fourth quarter worth $25,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina in the fourth quarter worth about $26,000. Laurel Wealth Advisors LLC bought a new stake in shares of Illumina during the 4th quarter worth about $26,000. Activest Wealth Management boosted its stake in shares of Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina during the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Trading Up 1.7%

Shares of ILMN stock opened at $223.22 on Tuesday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $223.97. The stock has a market cap of $33.71 billion, a price-to-earnings ratio of 41.65, a P/E/G ratio of 3.09 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a fifty day moving average of $189.13 and a 200-day moving average of $153.14.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm's revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent analyst reports. Barclays raised their price objective on Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a research note on Friday, July 31st. TD Cowen lifted their price target on shares of Illumina from $192.00 to $210.00 and gave the company a "hold" rating in a research report on Friday, July 31st. Wall Street Zen raised shares of Illumina from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a "hold" rating in a research note on Wednesday, August 5th. Finally, Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $188.40.

Insider Buying and Selling at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 2,095,958 shares of company stock valued at $401,720,974. 2.90% of the stock is currently owned by company insiders.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source